Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.

Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R.

Oncotarget. 2017 Oct 19;8(57):97290-97303. doi: 10.18632/oncotarget.21932. eCollection 2017 Nov 14.

2.

MPS1 kinase as a potential therapeutic target in medulloblastoma.

Alimova I, Ng J, Harris P, Birks D, Donson A, Taylor MD, Foreman NK, Venkataraman S, Vibhakar R.

Oncol Rep. 2016 Nov;36(5):2633-2640. doi: 10.3892/or.2016.5085. Epub 2016 Sep 12.

3.

Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.

Amani V, Prince EW, Alimova I, Balakrishnan I, Birks D, Donson AM, Harris P, Levy JM, Handler M, Foreman NK, Venkataraman S, Vibhakar R.

BMC Cancer. 2016 Aug 18;16:647. doi: 10.1186/s12885-016-2690-6.

4.

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.

Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R.

Oncotarget. 2016 Aug 16;7(33):53881-53894. doi: 10.18632/oncotarget.10692.

5.

[Open, non-comparative phase III clinical study to evaluate the efficacy and safety of sapropterin in patients with phenylketonuria and hyperphenylalaninemia].

Bushueva TV, Kuzenkova LM, Borovik TÉ, Nazarenko LP, Seitova GN, Filimonova MN, Pichkur NA, Samonenko NV, Shkurko TA, Akhmadeeva ÉN, Mardanova AK, Garifullina ÉR, Kovtun OP, Bazhenova IuL, Alimova IL, Kostiakova EA, Minaĭcheva LI, Saliukova OA, Sivokha VM, Rozenson OL.

Vestn Ross Akad Med Nauk. 2014;(7-8):69-77. Russian.

PMID:
25563006
6.

Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.

Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, Griesinger A, Amani V, Cristiano B, Remke M, Taylor MD, Handler M, Foreman NK, Vibhakar R.

Oncotarget. 2014 May 15;5(9):2355-71.

7.

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.

Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R.

Mol Cancer. 2014 Mar 24;13:72. doi: 10.1186/1476-4598-13-72.

8.
9.

MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma.

Venkataraman S, Birks DK, Balakrishnan I, Alimova I, Harris PS, Patel PR, Handler MH, Dubuc A, Taylor MD, Foreman NK, Vibhakar R.

J Biol Chem. 2013 Jan 18;288(3):1918-28. doi: 10.1074/jbc.M112.396762. Epub 2012 Dec 4.

10.

Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.

Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R.

Neuro Oncol. 2013 Feb;15(2):149-60. doi: 10.1093/neuonc/nos285. Epub 2012 Nov 28.

11.

Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.

Whiteway SL, Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Foreman NK, Vibhakar R.

J Neurooncol. 2013 Jan;111(2):113-21. doi: 10.1007/s11060-012-1000-7. Epub 2012 Nov 9.

12.

[Current approaches to the study of carcinogenic safety, antineoplastic, anticarcinogenic and geroprotective effects of various pharmacologic preparations].

Anisimov VN, Zabezhinskiĭ MA, Popovich IG, Pliss GB, Bespalov VG, Aleksandrov VA, Stukov AN, Anikin IV, Alimova IN, Egormin PA, Panchenko AV, Piskunova TS, Semenchenko AV, Tyndyk ML, Iurova MN.

Vopr Onkol. 2012;58(1):7-18. Review. Russian. No abstract available.

PMID:
22629822
13.

Rodent models for the preclinical evaluation of drugs suitable for pharmacological intervention in aging.

Anisimov VN, Zabezhinski MA, Popovich IG, Pliss GB, Bespalov VG, Alexandrov VA, Stukov AN, Anikin IV, Alimova IN, Egormin PА, Panchenko AV, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN.

Expert Opin Drug Discov. 2012 Jan;7(1):85-95. doi: 10.1517/17460441.2012.642361. Epub 2011 Dec 1. Review.

PMID:
22468896
14.

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.

Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R.

BMC Cancer. 2012 Mar 5;12:80. doi: 10.1186/1471-2407-12-80.

15.

Targeting the enhancer of zeste homologue 2 in medulloblastoma.

Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA, Dubuc A, Taylor MD, Foreman NK, Vibhakar R.

Int J Cancer. 2012 Oct 15;131(8):1800-9. doi: 10.1002/ijc.27455. Epub 2012 Jul 30.

16.

Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Venkataraman S, Alimova I, Tello T, Harris PS, Knipstein JA, Donson AM, Foreman NK, Liu AK, Vibhakar R.

J Neurooncol. 2012 May;107(3):517-26. doi: 10.1007/s11060-011-0795-y. Epub 2012 Jan 15.

17.

Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.

Knipstein JA, Birks DK, Donson AM, Alimova I, Foreman NK, Vibhakar R.

Neuro Oncol. 2012 Feb;14(2):175-83. doi: 10.1093/neuonc/nor208. Epub 2011 Dec 8.

18.

MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence.

Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R.

PLoS One. 2010 Jun 21;5(6):e10748. doi: 10.1371/journal.pone.0010748.

19.

Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation.

Wang A, Alimova IN, Luo P, Jong A, Triche TJ, Wu L.

FASEB J. 2010 Mar;24(3):833-43. doi: 10.1096/fj.09-142976. Epub 2009 Nov 16.

20.

Metformin induces unique biological and molecular responses in triple negative breast cancer cells.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD.

Cell Cycle. 2009 Jul 1;8(13):2031-40. Epub 2009 Jul 21.

PMID:
19440038

Supplemental Content

Loading ...
Support Center